{"id":"ventavis","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Bronchospasm","Chronic obstructive lung disease","Hepatic failure","Low blood pressure","Mild to Moderate Hypotension","Pulmonary edema"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL5315118","moleculeType":"Small molecule","molecularWeight":"481.63"},"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype"},"_scrapedAt":"2026-03-28T04:07:14.814Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Pulmonary arterial hypertension","diseaseId":"pulmonary-arterial-hypertension","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07498309","phase":"PHASE3","title":"Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-09","conditions":"Vaso-Occlusive Crises, Sickle Cell Disease","enrollment":144},{"nctId":"NCT07478094","phase":"","title":"Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-04-01","conditions":"Pulmonary Hypertension Due to Lung Diseases","enrollment":50},{"nctId":"NCT07450469","phase":"","title":"Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude","status":"NOT_YET_RECRUITING","sponsor":"Institute of Mountain Emergency Medicine","startDate":"2026-05","conditions":"Frostbite, Altitude, Field Physician Care","enrollment":10},{"nctId":"NCT07457762","phase":"NA","title":"AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-05-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":72},{"nctId":"NCT07424378","phase":"PHASE4","title":"Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-02","conditions":"Frostbite","enrollment":66},{"nctId":"NCT07356375","phase":"","title":"Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":32},{"nctId":"NCT07263958","phase":"NA","title":"Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD)","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-12-10","conditions":"Pulmnary Hypertension, COPD, Pulmonary Hypertension Secondary to Lung Disease and/or Hypoxia","enrollment":15},{"nctId":"NCT04583046","phase":"NA","title":"Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2020-11-02","conditions":"Lung Cancer (Including Metastatic Cancer), Pulmonary Infection","enrollment":78},{"nctId":"NCT01347216","phase":"","title":"COMPERA / COMPERA-KIDS","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2007-07-01","conditions":"Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)","enrollment":14000},{"nctId":"NCT06319274","phase":"PHASE2","title":"Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure","status":"RECRUITING","sponsor":"Pär Johansson","startDate":"2024-04-15","conditions":"Acute Respiratory Failure, Endothelial Dysfunction, Pulmonary Infection","enrollment":450},{"nctId":"NCT03867097","phase":"PHASE2","title":"Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)","status":"COMPLETED","sponsor":"Civi Biopharma, Inc.","startDate":"2019-03-07","conditions":"Raynaud Phenomenon Secondary to Systemic Sclerosis","enrollment":34},{"nctId":"NCT04040322","phase":"PHASE3","title":"Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)","status":"COMPLETED","sponsor":"Civi Biopharma, Inc.","startDate":"2019-10-14","conditions":"Raynaud's Phenomenon Secondary to Systemic Sclerosis","enrollment":198},{"nctId":"NCT00709956","phase":"PHASE3","title":"Iloprost Power 15 in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2008-07","conditions":"Pulmonary Arterial Hypertension","enrollment":64},{"nctId":"NCT00302211","phase":"PHASE3","title":"The \"VISION\" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Actelion","startDate":"2006-02-01","conditions":"Pulmonary Hypertension","enrollment":67},{"nctId":"NCT00902603","phase":"","title":"Ventavis® Registry Protocol","status":"TERMINATED","sponsor":"Actelion","startDate":"2009-03","conditions":"Pulmonary Arterial Hypertension","enrollment":148},{"nctId":"NCT02170519","phase":"PHASE4","title":"Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide","status":"TERMINATED","sponsor":"Duke University","startDate":"2006-09","conditions":"Pulmonary Hypertension","enrollment":27},{"nctId":"NCT02825160","phase":"","title":"Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-08-01","conditions":"Hypertension, Pulmonary","enrollment":282},{"nctId":"NCT03788837","phase":"PHASE3","title":"ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-07-03","conditions":"Septic Shock Hyperdynamic","enrollment":240},{"nctId":"NCT05411107","phase":"PHASE2","title":"Oral Iloprost for the Prevention of Lung Cancer In Former Smokers","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-01","conditions":"Bronchial Epithelial Dysplasia, Chronic Obstructive Pulmonary Disease, Lung Carcinoma","enrollment":""},{"nctId":"NCT03903939","phase":"PHASE2","title":"Infusion of Prostacyclin vs Placebo for 72-hours in Trauma Patients With Haemorrhagic Shock Suffering From Organ Failure","status":"COMPLETED","sponsor":"Pär Johansson","startDate":"2019-05-22","conditions":"Multi Organ Failure","enrollment":228},{"nctId":"NCT04123444","phase":"PHASE2, PHASE3","title":"Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure","status":"COMPLETED","sponsor":"Jakob Stensballe, MD, PhD","startDate":"2019-10-30","conditions":"Septic Shock","enrollment":279},{"nctId":"NCT04420741","phase":"PHASE2","title":"Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure","status":"COMPLETED","sponsor":"Pär Johansson","startDate":"2020-06-15","conditions":"COVID-19, Respiratory Failure","enrollment":80},{"nctId":"NCT03044314","phase":"PHASE4","title":"Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension","status":"TERMINATED","sponsor":"Duke University","startDate":"2017-07-21","conditions":"Pulmonary Hypertension","enrollment":27},{"nctId":"NCT00561223","phase":"NA","title":"Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2006-11","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension","enrollment":10},{"nctId":"NCT02237183","phase":"PHASE1","title":"Iloprost in Preventing Lung Cancer in Former Smokers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-05","conditions":"Lung Carcinoma","enrollment":34},{"nctId":"NCT04543682","phase":"PHASE1, PHASE2","title":"A Clinical Trial Investigating Iloprost as Medication to Improve Bone Healing in Patients With Proximal Humeral Fracture","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2022-05-12","conditions":"Proximal Humeral Fracture","enrollment":30},{"nctId":"NCT02565030","phase":"","title":"Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2015-02","conditions":"Chronic Thromboembolic Pulmonary Hypertension, Idiopathic Pulmonary Arterial Hypertension","enrollment":1200},{"nctId":"NCT04445246","phase":"PHASE2","title":"Inhaled Iloprost for Suspected COVID-19 Respiratory Failure","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2020-05-23","conditions":"COVID-19, ARDS, Human, Hypoxemic Respiratory Failure","enrollment":40},{"nctId":"NCT05204784","phase":"NA","title":"Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Peter Korsten","startDate":"2022-02-28","conditions":"Systemic Sclerosis, Raynaud Phenomenon, Digital Ulcer","enrollment":30},{"nctId":"NCT03111212","phase":"PHASE3","title":"Iloprost in Acute Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2019-06-25","conditions":"Respiratory Distress Syndrome, Adult","enrollment":150},{"nctId":"NCT04927039","phase":"NA","title":"Effects of Iloprost on Oxygenation During One-lung Ventilation in Supine-positioned Patients","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2021-06-24","conditions":"Mediastinal Mass","enrollment":60},{"nctId":"NCT03293407","phase":"","title":"Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-01","conditions":"Hypertension, Pulmonary","enrollment":31},{"nctId":"NCT02685618","phase":"PHASE2","title":"Endothelial Dysfunction in Resuscitated Cardiac Arrest","status":"COMPLETED","sponsor":"Pär Johansson","startDate":"2016-02","conditions":"Cardiac Arrest","enrollment":50},{"nctId":"NCT04598191","phase":"NA","title":"Effect of Intraoperative Iloprost Inhalant on Hemodynamic Stability in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2020-11-04","conditions":"Coronary Artery Occlusive Disease","enrollment":100},{"nctId":"NCT00084409","phase":"PHASE2","title":"Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2001-11","conditions":"Lung Cancer, Precancerous Condition","enrollment":152},{"nctId":"NCT02482402","phase":"PHASE2","title":"Iloprost for Bridging to Heart Transplantation in PH","status":"WITHDRAWN","sponsor":"Heidelberg University","startDate":"2015-02","conditions":"Chronic Left Ventricular Failure, Pulmonary Hypertension","enrollment":""},{"nctId":"NCT03620526","phase":"PHASE4","title":"Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-11-29","conditions":"Heart Failure With Normal Ejection Fraction","enrollment":34},{"nctId":"NCT03380325","phase":"NA","title":"The Effect of Iloprost on Capillary Recruitment and Insulin Sensitivity in Type 2 Diabetes","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2016-05-11","conditions":"Diabetes Mellitus, Type 2, Insulin Sensitivity/Resistance","enrollment":15},{"nctId":"NCT03936140","phase":"NA","title":"The Effect of Iloprost on Oxygenation During One-lung Ventilation for Lung Surgery","status":"COMPLETED","sponsor":"Seoul St. Mary's Hospital","startDate":"2018-01-04","conditions":"Lung Cancer","enrollment":72},{"nctId":"NCT01389271","phase":"","title":"Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-02-03","conditions":"Pulmonary Hypertension","enrollment":118},{"nctId":"NCT01971450","phase":"","title":"Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-11-21","conditions":"Hypertension, Pulmonary","enrollment":89},{"nctId":"NCT01054105","phase":"","title":"Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2010-10","conditions":"Pulmonary Arterial Hypertension","enrollment":73},{"nctId":"NCT03365479","phase":"NA","title":"Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2017-05-01","conditions":"Pulmonary Hypertension, Pulmonary Arterial Hypertension","enrollment":30},{"nctId":"NCT01774058","phase":"PHASE2","title":"The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation","status":"UNKNOWN","sponsor":"Prim PD Dr Afshin Assadian","startDate":"2012-10","conditions":"Diabetes, Arteriosclerosis, Peripheral Arterial Occlusive Disease","enrollment":100},{"nctId":"NCT02032836","phase":"PHASE1, PHASE2","title":"Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-10","conditions":"Pulmonary Arterial Hypertension","enrollment":27},{"nctId":"NCT01389206","phase":"","title":"Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-06-01","conditions":"Pulmonary Arterial Hypertension","enrollment":797},{"nctId":"NCT03610217","phase":"NA","title":"Pragmatic Clinical Trials in Scleroderma","status":"UNKNOWN","sponsor":"University of West London","startDate":"2018-10","conditions":"Scleroderma, Systemic, Sclerosis, Systemic","enrollment":400},{"nctId":"NCT02784899","phase":"NA","title":"Effect of Iloprost on Pulmonary Oxygenation in Patients With Low Diffusing Capacity During One-lung Ventilation","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2015-10-08","conditions":"Lung Cancer","enrollment":40},{"nctId":"NCT01894035","phase":"","title":"Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-09-23","conditions":"Pulmonary Hypertension","enrollment":13},{"nctId":"NCT03406988","phase":"NA","title":"Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers","status":"UNKNOWN","sponsor":"ASST Gaetano Pini-CTO","startDate":"2017-07-18","conditions":"Systemic Sclerosis, Digital Ulcer","enrollment":46},{"nctId":"NCT01469169","phase":"PHASE3","title":"Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-06-19","conditions":"Hypertension, Pulmonary","enrollment":27},{"nctId":"NCT01781052","phase":"","title":"Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-09-11","conditions":"Pulmonary Arterial Hypertension","enrollment":17},{"nctId":"NCT01355380","phase":"","title":"Efficacy of Ventavis Used in Real-life Setting.","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-08-05","conditions":"Pulmonary Arterial Hypertension","enrollment":55},{"nctId":"NCT02204852","phase":"PHASE2","title":"Co-administration of Iloprost and Eptifibatide in Septic Shock Patients","status":"COMPLETED","sponsor":"Sisse R. Ostrowski, MD PhD DMSc","startDate":"2014-09","conditions":"Septic Shock","enrollment":18},{"nctId":"NCT02826252","phase":"","title":"Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-09-15","conditions":"Hypertension, Pulmonary","enrollment":64},{"nctId":"NCT01941225","phase":"PHASE2","title":"Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2013-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":24},{"nctId":"NCT01598441","phase":"PHASE3","title":"Multicenter Study of Iloprost Inhaled in Pulmonary Hypertension After Repair of Congenital Heart Diseases (CHD)","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-06","conditions":"Pulmonary Hypertension","enrollment":8},{"nctId":"NCT02490657","phase":"NA","title":"Effects of Iloprost on Pulmonary Hemodynamics and Oxygenation in Patients of Chronic Obstructive Pulmonary Disease During One-lung Ventilation","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2015-07","conditions":"Video-assisted Thoracoscopic Surgery, Chronic Obstructive Pulmonary Disease","enrollment":44},{"nctId":"NCT01532544","phase":"PHASE2","title":"Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis","status":"TERMINATED","sponsor":"Thrombologic ApS","startDate":"2012-06","conditions":"Pneumonia","enrollment":5},{"nctId":"NCT01266265","phase":"","title":"Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2010-12","conditions":"Pulmonary Arterial Hypertension","enrollment":1333},{"nctId":"NCT01467791","phase":"","title":"Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2011-11","conditions":"Sarcoidosis, Pulmonary Hypertension","enrollment":300},{"nctId":"NCT01310751","phase":"PHASE2, PHASE3","title":"Study of Inhaled Iloprost in Pediatric Pulmonary Hypertension (PH) After Surgery","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2011-01","conditions":"Pulmonary Hypertension","enrollment":36},{"nctId":"NCT01437878","phase":"PHASE2","title":"Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Actelion","startDate":"2012-03","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension","enrollment":2},{"nctId":"NCT00709098","phase":"PHASE3","title":"Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2008-09","conditions":"Pulmonary Arterial Hypertension","enrollment":49},{"nctId":"NCT02238535","phase":"PHASE2","title":"Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension","status":"UNKNOWN","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2014-09","conditions":"Residual Pulmonary Hypertension","enrollment":60},{"nctId":"NCT00724321","phase":"PHASE1","title":"Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction at Altitude","status":"WITHDRAWN","sponsor":"Loma Linda University","startDate":"2008-07","conditions":"Hypoxic Pulmonary Vasoconstriction","enrollment":""},{"nctId":"NCT01458041","phase":"","title":"Iloprost Therapy in Patients With Critical Limb Ischemia","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-08","conditions":"Peripheral Arterial Disease","enrollment":126},{"nctId":"NCT00250640","phase":"","title":"Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-04","conditions":"Hypertension, Pulmonary","enrollment":106},{"nctId":"NCT01319045","phase":"NA","title":"Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2011-06","conditions":"Pulmonary Arterial Hypertension, Congenital Heart Disease, Eisenmenger's Syndrome","enrollment":5},{"nctId":"NCT00981591","phase":"PHASE1, PHASE2","title":"Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients","status":"WITHDRAWN","sponsor":"Seattle Children's Hospital","startDate":"2009-09","conditions":"Pulmonary Hypertension, Neonatal Hypoxic Respiratory Failure, Persistent Pulmonary Hypertension of Newborn","enrollment":""},{"nctId":"NCT01468545","phase":"","title":"Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-10","conditions":"Pulmonary Arterial Hypertension","enrollment":38},{"nctId":"NCT00409526","phase":"PHASE4","title":"Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2006-12","conditions":"Pulmonary Hypertension","enrollment":1},{"nctId":"NCT01712997","phase":"PHASE3","title":"Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2012-09","conditions":"Pulmonary Arterial Hypertension","enrollment":90},{"nctId":"NCT01836263","phase":"","title":"Prevention and Treatment of Digital Ulcers in Systemic Sclerosis","status":"UNKNOWN","sponsor":"marco matucci cerinic","startDate":"2013-04","conditions":"Systemic Sclerosis, Ulcer","enrollment":420},{"nctId":"NCT00403650","phase":"PHASE4","title":"Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2006-11","conditions":"Sarcoidosis, Pulmonary Arterial Hypertension","enrollment":20},{"nctId":"NCT00467896","phase":"PHASE2","title":"The \"Power 15 Study\": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting","status":"TERMINATED","sponsor":"Actelion","startDate":"2006-09","conditions":"Pulmonary Hypertension","enrollment":62},{"nctId":"NCT00723554","phase":"PHASE3","title":"Iloprost Power Disc-15 in Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Actelion","startDate":"2008-07","conditions":"Pulmonary Arterial Hypertension","enrollment":63},{"nctId":"NCT00741819","phase":"PHASE4","title":"Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2008-09","conditions":"Pulmonary Arterial Hypertension","enrollment":73},{"nctId":"NCT00927654","phase":"PHASE3","title":"Iloprost in High Risk Cardiac Surgical Patients","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2009-06","conditions":"Pulmonary Hypertension","enrollment":253},{"nctId":"NCT00235521","phase":"NA","title":"Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2005-05","conditions":"Pulmonary Hypertension","enrollment":15},{"nctId":"NCT01718288","phase":"PHASE4","title":"Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb)","status":"COMPLETED","sponsor":"Fadoi Foundation, Italy","startDate":"2006-11","conditions":"Peripheral Arterial Disease","enrollment":150},{"nctId":"NCT00120380","phase":"PHASE4","title":"Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2004-09","conditions":"Hypertension","enrollment":40},{"nctId":"NCT01274481","phase":"PHASE1","title":"Iloprost Effects on Gas Exchange and Pulmonary Mechanics","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2011-03","conditions":"Acute Respiratory Distress Syndrome, Acute Lung Injury, Pulmonary Hypertension","enrollment":20},{"nctId":"NCT01649739","phase":"PHASE4","title":"Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2012-09","conditions":"Pulmonary Arterial Hypertension","enrollment":20},{"nctId":"NCT01320878","phase":"PHASE2","title":"Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension After Repair of Congenital Heart Disease","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2007-10","conditions":"Pulmonary Hypertension","enrollment":64},{"nctId":"NCT01549171","phase":"","title":"Enhanced Assisted Reproductive Technology Pregnancy Rate by Prostacyclin Analog (Iloprost)","status":"UNKNOWN","sponsor":"Fertility Specialists of Houston","startDate":"2010-01","conditions":"Pregnancy","enrollment":100},{"nctId":"NCT01082484","phase":"PHASE1, PHASE2","title":"Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2010-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT01209533","phase":"EARLY_PHASE1","title":"Inhaled Iloprost in Mild Asthma","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-09","conditions":"Asthma","enrollment":24},{"nctId":"NCT01383083","phase":"","title":"Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease","status":"UNKNOWN","sponsor":"Maryknoll Medical Center","startDate":"2010-11","conditions":"Pulmonary Arterial Hypertension","enrollment":42},{"nctId":"NCT01179776","phase":"PHASE1, PHASE2","title":"Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Thrombologic ApS","startDate":"2010-09","conditions":"Myocardial Infarct","enrollment":16},{"nctId":"NCT01062282","phase":"","title":"Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-07","conditions":"Pulmonary Hypertension","enrollment":41},{"nctId":"NCT00086463","phase":"PHASE2","title":"Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2004-06","conditions":"Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension","enrollment":60},{"nctId":"NCT01283958","phase":"","title":"The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2007-09","conditions":"Eisenmenger's Syndrome","enrollment":12},{"nctId":"NCT01116063","phase":"PHASE4","title":"Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)","status":"UNKNOWN","sponsor":"Carmel Medical Center","startDate":"2010-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":15},{"nctId":"NCT00185315","phase":"PHASE3","title":"Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2000-02","conditions":"Hypertension, Pulmonary","enrollment":71},{"nctId":"NCT00453414","phase":"PHASE2","title":"Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension","status":"WITHDRAWN","sponsor":"Actelion","startDate":"2006-07","conditions":"Pulmonary Arterial Hypertension","enrollment":""},{"nctId":"NCT00109681","phase":"PHASE2","title":"Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Actelion","startDate":"2005-04","conditions":"Pulmonary Fibrosis, Pulmonary Hypertension","enrollment":50},{"nctId":"NCT00414687","phase":"PHASE2","title":"Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"1998-07","conditions":"Hypertension, Pulmonary","enrollment":63},{"nctId":"NCT00882947","phase":"","title":"Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-02","conditions":"Primary Hypertension","enrollment":38},{"nctId":"NCT00216931","phase":"NA","title":"Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost","status":"WITHDRAWN","sponsor":"Lund University Hospital","startDate":"2006-05","conditions":"Persistent Pulmonary Hypertension, Respiratory Distress Syndrome","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":2150,"reaction":"DEATH"},{"count":1315,"reaction":"DYSPNOEA"},{"count":694,"reaction":"HEADACHE"},{"count":570,"reaction":"COUGH"},{"count":534,"reaction":"PULMONARY ARTERIAL HYPERTENSION"},{"count":533,"reaction":"FATIGUE"},{"count":514,"reaction":"DIZZINESS"},{"count":454,"reaction":"PNEUMONIA"},{"count":437,"reaction":"NAUSEA"},{"count":413,"reaction":"PULMONARY HYPERTENSION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":18,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"Ventavis","genericName":"Ventavis","companyName":"Meshalkin Research Institute of Pathology of Circulation","companyId":"meshalkin-research-institute-of-pathology-of-circulation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ventavis is a medication used to treat conditions such as pulmonary arterial hypertension, scleroderma, and Raynaud's phenomenon, where blood vessels are constricted and blood flow is impaired. It works as a prostanoid IP receptor agonist, a type of small molecule that activates the prostacyclin receptor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}